Single-Dose Pharmacokinetics of a Pleconaril (VP63843) Oral Solution and Effect of Food
- 1 October 1998
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (10) , 2706-2709
- https://doi.org/10.1128/aac.42.10.2706
Abstract
Pleconaril is an orally active broad-spectrum antipicornaviral agent which demonstrates excellent penetration into the central nervous system, liver, and nasal epithelium. We report the results of a randomized two-way crossover study designed to characterize the disposition of a single dose (200 mg) of pleconaril oral solution in fed and fasting humans. Twelve healthy adult subjects (18.7 to 39 years of age) participated in this study. Each subject received a single 200-mg dose of pleconaril oral solution, both coadministered with a standard English breakfast and following a 10-h predose fast. There was a minimum 7-day washout period between pleconaril doses. Repeated blood samples ( n = 10) were obtained over 24 h postdose, and the pleconaril level in plasma was quantified by gas chromatography. Plasma concentration-versus-time data were curve fitted for each subject by using a nonlinear weighted least-squares algorithm, and pharmacokinetic parameters were determined from the polyexponential estimates. Pleconaril disposition was best characterized by a one-compartment open model with first-order absorption. The apparent bioavailability of pleconaril oral solution was significantly increased with the administration of food. The area under the concentration-time curve and maximum concentration of pleconaril in plasma achieved following the standard English breakfast (i.e., 9.08 ± 3.23 mg/liter · h and 1.14 ± 0.58 mg/liter, respectively) were 2.2- and 2.5-fold higher, respectively than those achieved in the fasting state (i.e., 4.08 ± 2.74 mg/liter · h and 0.46 ± 0.30 mg/liter, respectively). Mean plasma pleconaril concentrations 12 h after a single 200-mg oral dose (fed, 0.25 ± 0.2 mg/liter; fasting, 0.11 ± 0.10 mg/liter) in healthy adults remained greater than that required to inhibit more than 90% of the enteroviruses in cell culture (i.e., 0.07 mg/liter). To enhance the oral bioavailability of pleconaril, coadministration with a fat-containing meal is recommended.Keywords
This publication has 10 references indexed in Scilit:
- Other viral agents of perinatal importance. Varicella, parvovirus, respiratory syncytial virus, and enterovirus.1997
- Other Viral Agents of Perinatal ImportanceClinics in Perinatology, 1997
- Nonpolio enteroviruses and the febrile young infant: epidemiologic, clinical and diagnostic aspectsThe Pediatric Infectious Disease Journal, 1996
- Neonatal Enterovirus Infection: Virology, Serology, and Effects of Intravenous Immune GlobulinClinical Infectious Diseases, 1995
- Enteroviral Infections of the Central Nervous SystemClinical Infectious Diseases, 1995
- PCR for the Diagnosis of Enteroviral MeningitisScandinavian Journal of Infectious Diseases, 1994
- Aseptic Meningitis in Infants <2 Years of Age: Diagnosis and EtiologyThe Journal of Infectious Diseases, 1993
- TREATMENT OF THE PICORNA VIRUS COMMON COLD BY INHIBITORS OF VIRAL UNCOATING AND ATTACHMENTAnnual Review of Microbiology, 1992
- Temporal and Geographic Patterns of Isolates of Nonpolio Enterovirus in the United States, 1970-1983The Journal of Infectious Diseases, 1986
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978